MEK Inhibitor
AZD6244 + Chemotherapy for Advanced Cancer
This study is evaluating whether a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated
Imaging
Tomosynthesis vs. Contrast-Enhanced Mammography for Breast Cancer
This trial aims to see if using contrast-enhanced mammography (CEM) can better detect breast cancer in women who have had it before. CEM uses a special dye to make cancerous tissues more visible on the mammogram. The goal is to improve detection rates without significantly increasing false positives. Contrast-enhanced mammography (CEM) is an imaging tool for breast cancer detection that combines conventional mammography with a special dye to improve cancer detection.
DHODH Inhibitor
Leflunomide for Triple Negative Breast Cancer
This trial is testing the safety and effectiveness of leflunomide, a daily oral medication, in women with aggressive triple negative breast cancer. The drug aims to block a substance that helps cancer cells grow. The study focuses on women who have already tried other treatments.
Popular Filters
Trials for Ductal Carcinoma Patients
Monoclonal Antibodies
Combination Therapy for Breast Cancer
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
PD-L1 Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Hormone Therapy
Endocrine Therapy for Low-Risk Breast Cancer
This trial is testing if hormone therapy alone can effectively treat breast cancer in women aged 70 or older with certain types of tumors. The therapy works by blocking estrogen, which helps stop cancer cells from growing. Researchers believe this approach could be enough to control the cancer without needing more aggressive treatments.
Hormone Therapy
Endocrine Therapy Without Radiotherapy for Breast Cancer
This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
This trial is comparing two treatments for hormone receptor positive, HER2 negative advanced breast cancer. One group will receive abemaciclib + fulvestrant, and the other will just receive fulvestrant. The study will last about 9 months for each participant.
Trials for LABC Patients
Monoclonal Antibodies
Combination Therapy for Breast Cancer
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
PD-L1 Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Hormone Therapy
Endocrine Therapy for Low-Risk Breast Cancer
This trial is testing if hormone therapy alone can effectively treat breast cancer in women aged 70 or older with certain types of tumors. The therapy works by blocking estrogen, which helps stop cancer cells from growing. Researchers believe this approach could be enough to control the cancer without needing more aggressive treatments.
Hormone Therapy
Endocrine Therapy Without Radiotherapy for Breast Cancer
This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
This trial is comparing two treatments for hormone receptor positive, HER2 negative advanced breast cancer. One group will receive abemaciclib + fulvestrant, and the other will just receive fulvestrant. The study will last about 9 months for each participant.
Trials for Metastatic Patients
Monoclonal Antibodies
Combination Therapy for Breast Cancer
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
PD-L1 Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
This trial is comparing two treatments for hormone receptor positive, HER2 negative advanced breast cancer. One group will receive abemaciclib + fulvestrant, and the other will just receive fulvestrant. The study will last about 9 months for each participant.
Chemotherapy
Personalized Adaptive Novel Agents for Breast Cancer
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Trials for ER Positive Patients
Monoclonal Antibodies
Combination Therapy for Breast Cancer
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
Hormone Therapy
Endocrine Therapy for Low-Risk Breast Cancer
This trial is testing if hormone therapy alone can effectively treat breast cancer in women aged 70 or older with certain types of tumors. The therapy works by blocking estrogen, which helps stop cancer cells from growing. Researchers believe this approach could be enough to control the cancer without needing more aggressive treatments.
Hormone Therapy
Endocrine Therapy Without Radiotherapy for Breast Cancer
This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
Chemotherapy
Personalized Adaptive Novel Agents for Breast Cancer
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Trials for PR Positive Patients
Monoclonal Antibodies
Combination Therapy for Breast Cancer
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
Hormone Therapy
Endocrine Therapy Without Radiotherapy for Breast Cancer
This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
Chemotherapy
Personalized Adaptive Novel Agents for Breast Cancer
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Monoclonal Antibodies
Pembrolizumab + Chemotherapy for Breast Cancer
This trial will assess if pembrolizumab, when combined with chemotherapy, is more effective in treating hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer than chemotherapy alone. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) or overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1 and ≥10.
Chemotherapy
Focused Ultrasound + Gemcitabine for Breast Cancer
This trial will test whether focused ultrasound ablation, low-dose gemcitabine, or a combination of the two can help early-stage breast cancer patients by affecting cells in the immune system. The hypothesis is that the combination of the two will be more effective and have fewer negative side effects than either treatment alone.
Phase 3 Trials
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
This trial is comparing two treatments for hormone receptor positive, HER2 negative advanced breast cancer. One group will receive abemaciclib + fulvestrant, and the other will just receive fulvestrant. The study will last about 9 months for each participant.
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Monoclonal Antibodies
Pembrolizumab + Chemotherapy for Breast Cancer
This trial will assess if pembrolizumab, when combined with chemotherapy, is more effective in treating hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer than chemotherapy alone. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) or overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1 and ≥10.
Trials With No Placebo
Monoclonal Antibodies
Combination Therapy for Breast Cancer
This trial is testing a new combination of drugs to treat metastatic hormone receptor-positive, HER2-positive breast cancer. The goal is to establish the safety and efficacy of this new combination and to examine potential biomarkers of response to the treatment.
PD-L1 Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Hormone Therapy
Endocrine Therapy for Low-Risk Breast Cancer
This trial is testing if hormone therapy alone can effectively treat breast cancer in women aged 70 or older with certain types of tumors. The therapy works by blocking estrogen, which helps stop cancer cells from growing. Researchers believe this approach could be enough to control the cancer without needing more aggressive treatments.
Hormone Therapy
Endocrine Therapy Without Radiotherapy for Breast Cancer
This trial will study whether it's safe to forgo radiation treatment after lumpectomy surgery for postmenopausal women with hormone-positive, Her2-negative tumors who have a low risk of cancer recurrence.
View More Related Trials
Frequently Asked Questions
Introduction to breast cancer
What are the top hospitals conducting breast cancer research?
When it comes to cutting-edge clinical trials in the field of breast cancer, these top hospitals are leading the way. In Boston, the Dana-Farber Cancer Institute is setting an impressive example with nine active breast cancer trials and a remarkable history of 218 all-time trials dedicated to this condition. The institute's commitment to research dates back to its first recorded breast cancer trial in 1998, making it one of the pioneers in this crucial area.
Meanwhile, across state lines in New york City, Memorial Sloan Kettering Cancer Center stands as a beacon of hope for patients battling breast cancer. With eight ongoing breast cancer trials and an astounding record of 219 completed studies, this renowned institution has been at the forefront since their first recorded trial back in 1994.
Not too far from Boston lies Massachusetts General Hospital—a powerhouse when it comes to medical advancements and breakthroughs. Currently conducting seven active breast cancer trials while having completed a total of 157 studies over time shows their dedication towards fighting against this disease since recording their initial trial on this subject matter dating back until 1997.
Moving westward brings us to Washington University School of Medicine located in Saint Louis where they actively contribute through seven ongoing investigations on latest treatment methods available towards such cases which adds onto their already accomplished tally that sits at one hundred-thirty-seven; starting off with bringing forth progressive approaches by initiating investigation into potential treatments related solely towards combatting Breast Cancer around two decades prior (2000).
Lastly but not least significant Florida Cancer Specialists situated within Fort Myers plays key role whilst staying relatively smaller-scale; currently hosting six ongoing clinical tests focusing primarily on forward thinking yet practical solutions.Their proactive approach can be traced back almost three decades ago when they conducted initial pioneering investigations with relation only specificially targeting Breast Cancers starting from nineteen-ninety five.These respective institutions signify not just promises for individuals affected by Breast Cancers but also mark critical milestones toward advancement nationwide. The combined efforts of these top hospitals serve as a testament of human endeavor to understand this disease in its entirety and strive towards discovering breakthroughs that ensure brighter futures for countless patients around the world
Which are the best cities for breast cancer clinical trials?
When it comes to breast cancer clinical trials, several cities in the United States stand out for their active research initiatives. Boston, Massachusetts leads with 39 ongoing trials focusing on treatments like Enzalutamide, Trastuzumab emtansine (T-DM1), and PF-07220060. Nashville, Tennessee follows closely behind with 36 trials studying similar interventions. Houston, Texas and New york City also contribute significantly to breast cancer research with 32 and 31 active trials respectively. Additionally, Denver, Colorado is recognized for its dedication to advancing treatment options through 30 ongoing studies. These cities serve as key centers of innovation and provide valuable opportunities for patients seeking participation in breast cancer clinical trials.
Which are the top treatments for breast cancer being explored in clinical trials?
In the realm of breast cancer clinical trials, several top treatments have emerged as potential game-changers. Abemaciclib is taking center stage with its involvement in four active trials and a remarkable 65 all-time breast cancer trials since its introduction in 2014. Trastuzumab follows closely behind, also participating in four ongoing trials and an impressive history of 325 all-time breast cancer studies dating back to 2000. Another contender making waves is Olaparib, currently being explored in three active trials and boasting an extensive portfolio of 50 all-time breast cancer studies starting from 2010. Additionally, the promising Imlunestrant has caught researchers' attention with two active trials and three all-time breast cancer studies since its recent debut in 2021. These innovative treatments continue to pave the way for advancements against this relentless disease.
What are the most recent clinical trials for breast cancer?
Exciting advancements are being made in breast cancer research through recent clinical trials. One notable trial is exploring the effectiveness of a new treatment regimen for breast cancer patients, with promising results seen in Phase 2. Another study focuses on the use of injections at a specific dosage to target breast cancer cells, showing potential benefits during its Phase 1 stage. Additionally, researchers are investigating the efficacy of imlunestrant and elacestrant in separate Phase 3 and combined Phase 1/Phase 2 trials respectively. Finally, denosumab's potential role as a treatment option for breast cancer patients is being evaluated through an ongoing Phase 3 trial that began earlier this year. These endeavors bring hope for improved outcomes and novel therapeutic approaches to combat this challenging disease.
What breast cancer clinical trials were recently completed?
A multitude of recent clinical trials have made significant strides in the field of breast cancer research. Among them, G1 Therapeutics, Inc. completed a trial for Trilaciclib in November 2021, while HiberCell, Inc. concluded their study on Pembrolizumab during the same month. In July 2021, Mayo Clinic successfully wrapped up a trial investigating Probiotic treatment for breast cancer patients. Additionally, numerous other trials conducted by various institutions and organizations have contributed to expanding our understanding and potential treatment options for this devastating disease.